Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Mar 09 2022 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference Feb 07 2022 Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Mar 09 2022 Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference Feb 07 2022 Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
Jan 06 2022 Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
